15.32
+1.06%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About HUTCHMED DRC
Its shares trade under the ticker HCM. It has been listed since 17 March 2016. In the fiscal year to 31 December 2025, it reported revenue of $550.0m and net income of $458.1m. At that date it held total assets of $1.75bn and shareholders' equity of $1.24bn.
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 17 Mar 2016
- Employees
- 1,988
- Website
- hutch-med.com ↗
- Head office
- 48TH FLOOR, CHEUNG KONG CENTER, HONG KONG
- Incorporated in
- E9
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- HUTCHMED develops Fruquintinib for colorectal cancer treatment in the US market.
- HUTCHMED's Savolitinib targets NSCLC and papillary RCC in global markets.
- HUTCHMED's Surufatinib is in development for pancreatic NET and pancreatic ductal adenocarcinoma.
Weaknesses
- HUTCHMED has 1988 employees in Hong Kong city.
- HUTCHMED is listed on the stock market since 17 March 2016.
- HUTCHMED operates in the Health Care sector with a focus on cancer therapeutics.
Opportunities
- HUTCHMED's Fruquintinib is approved for breast cancer treatment in the US.
- HUTCHMED's Savolitinib is being developed for gastric cancer treatment globally.
- HUTCHMED's Surufatinib targets non-pancreatic NET in international markets.
Threats
- HUTCHMED faces competition in the Health Care sector for cancer treatments.
- HUTCHMED's products are limited to specific cancer types like NSCLC and RCC.
- HUTCHMED's business is concentrated in the Health Care industry with no diversification.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.